First US biosimilar launch.
出版信息
Nat Biotechnol. 2015 Oct;33(10):1013. doi: 10.1038/nbt1015-1013b.
PMID:26448071
Abstract
摘要
相似文献
1
First US biosimilar launch.
Nat Biotechnol. 2015 Oct;33(10):1013. doi: 10.1038/nbt1015-1013b.
2
First biosimilar drug approved in the USA.
Lancet Oncol. 2015 Apr;16(4):e161. doi: 10.1016/S1470-2045(15)70088-4. Epub 2015 Mar 13.
3
Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
J Oncol Pract. 2017 Sep;13(9_suppl):7s-9s. doi: 10.1200/JOP.2017.026831.
4
Japanese regulatory authority's perspective on biosimilars.
Lancet Oncol. 2015 Mar;16(3):e101. doi: 10.1016/S1470-2045(14)71220-3.
5
Japanese regulatory authority's perspective on biosimilars - authors' reply.
Lancet Oncol. 2015 Mar;16(3):e102. doi: 10.1016/S1470-2045(15)70047-1.
6
New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
Expert Rev Anticancer Ther. 2015 Mar;15(3):331-8. doi: 10.1586/14737140.2015.993318. Epub 2014 Dec 25.
7
The Biosimilar Pipeline Seams Seem To Be Bursting.
Manag Care. 2017 Mar;26(3):24-25.
8
First biosimilar drug approved for sale in the United States.
J Natl Cancer Inst. 2015 Jul 3;107(7). doi: 10.1093/jnci/djv191. Print 2015 Jul.
9
First biosimilar drug set to enter US market.
Nature. 2015 Jan 15;517(7534):253-4. doi: 10.1038/517253a.
10
FDA approves biosimilar version of infliximab.
Am J Health Syst Pharm. 2016 May 15;73(10):604-6. doi: 10.2146/news160032.
本文引用的文献
1
First US biosimilar edges towards market.
Nat Biotechnol. 2015 Mar;33(3):222-3. doi: 10.1038/nbt0315-222.
2
Building a wall against biosimilars.
Nat Biotechnol. 2013 Apr;31(4):264. doi: 10.1038/nbt.2550.
Zotero 插件